• OPEN AN ACCOUNT
Indian Indices
Sensex
82,626.76 -1,048.16
( -1.25%)
Global Indices
Nasdaq
49,514.94 41.95
(0.08%)
Dow Jones
6,856.39 2.63
(0.04%)
Hang Seng
57,040.53 -599.31
(-1.04%)
Nikkei 225
10,448.94 46.50
(0.45%)
Forex
USD-INR
90.59 -0.07
(-0.07%)
EUR-INR
107.56 -0.26
(-0.24%)
GBP-INR
123.48 -0.32
(-0.26%)
JPY-INR
0.59 0.00
(0.20%)

EQUITY - MARKET SCREENER

Shalimar Paints Ltd
Industry :  Paints / Varnishes
BSE Code
ISIN Demat
Book Value()
509874
INE849C01026
19.2318684
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SHALPAINTS
0
512.23
EPS(TTM)
Face Value()
Div & Yield %
0
2
0
 

avatar industries ltd
Gland Pharma climbs on USFDA nod for allergy eye drug
Jan 08,2026
The said drug is therapeutically equivalent to the reference listed drug (RLD), Pataday Once Daily Relief, 0.7%, of Alcon Laboratories Inc (Alcon). The said drug indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.

The company’s consolidated net profit increased 12.3% to Rs 183.68 crore on 5.8% rise in net sales to Rs 1486.88 crore in Q2 FY26 over Q2 FY25.